PDF下载 ( 1323 KB)
Correlation of HLA-DRB1*15 allele with short term antiviral effect of adefovir dipivoxil
-
摘要: 目的探讨人类白细胞相关抗原DRB1*15（HLA-DRB1*15）等位基因位点与阿德福韦酯治疗慢性乙型肝炎（CHB）6个月时疗效的相关性。方法以阿德福韦酯治疗的CHB患者6个月时有效及无效病例（分别为52和42例）作为研究对象,采用序列特异性引物聚合酶链反应技术（PCR-SSP）对两组研究对象中HLA-DRB1*15基因位点进行检测并对此等位基因位点的频率进行比较分析。结果 HLA-DRB1*15等位基因位点在CHB及相同抗病毒疗效中分布与HBeAg无统计学差异,HLA-DRB1*15等位基因位点在治疗有效组和无效组中的频率分布差异存在统计学意义（χ2=5.050,P=0.025,OR=3.176,95%CI:1.127～8.951）。结论 HLA-DRB1*15在CHB及相同抗病毒疗效中的分布与HBeAg无相关性,HLA-DRB1*15可能是阿德福韦酯抗HBV有效的预测指标。Abstract: Objective To investigate the relationship between HLA-DRB1*15 allele and the efficacy of adefovir dipivoxil in chronic hepatitis B for six months.Methods 94 chronic hepatitis B patients treated with adefovir dipivoxil were selected and divided into 52 cases of effective group and 42 cases of ineffective group.HLA-DRB1*15 was detected by using the polymerase chain reaction sequence specific primer (PCR-SSP) , and the Frequencies of HLA-DRB1*15 were analyzed between the two groups.Results No significant difference was found in HLA-DRB1*15 frequency with hepatitis e antigen in chronic hepatitis B or in the same antiviral effect group.The frequency of HLA-DRB1*15 in effective group was significantly higher than that in ineffective group (χ2=5.050, P=0.025, OR=3.176, 95%CI:1.127 8.951) .Conclusion HLA-DRB1*15 allele in chronic hepatitis B or in the same antiviral effect group has no relationship distribution with hepatitis e antigen.HLA-DRB1*15 might be an effective treatment predictor marker of adefovir dipivoxil.
-
Key words:
- human leukocyte antigens /
- adefovir dipivoxil /
- hepatitis B
-
[1]骆峻, 金安娜, 吴旭东, 等.中国人群HLA-DRB1基因多态性与慢性肝炎关系的Meta分析[J].世界华人消化杂志, 2006, 14 (31) :3050-3054. [2]中华医学会.慢性乙型肝炎防治指南[J].实用肝脏病杂志, 2006, 9 (10) :8-18. [3]Olerup O, Zetterquist H.HLA-DR typing by PCR amplifica-tion with sequence-specific primers (PCR-SSP) in2 hours:An alternative to serological DR typing in clinical prac-tice including donor-recipient matching in cadaveric trans-plantations[J].Tissue Antigens, 1992, 39 (1) :225-235. [4]熊平, 扬颖, 龚非力.一种新的HLA-II类基因分型方法—PCR/SSP技术的建立[J].免疫学杂志, 1996, 12 (4) :258-261. [5]刘业云, 龚菁, 史罗明.阿德福韦治疗慢性乙型肝炎患者的疗效观察[J].实用临床医药杂志, 2007, 11 (4) :84. [6]Seigneres B, Aguesse-gemon S, Pichoud C, et al.Duck hep-atitis B virus polymerase gene mutants assosciated with resist-ance to lamivudine have a decreased replication capacity in vitro and in vivo[J].J Hepatol, 2001, 34 (1) :114-122. [7]王昕红, 张光文, 孙立华, 等.阿德福韦酯对慢性乙型肝炎患者外周T淋巴细胞亚群的影响[J].中国现代医生, 2010, 48 (20) :53-54. [8]江军, 蔡雄, 缪晓辉.阿德福韦酯对慢性乙型肝炎患者外周血干扰素和白细胞介素的影响[J].肝脏, 2006, 11 (2) :86-88. [9]Cooksley H, Chokshi S, Maayan Y, et al.Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhandced virus-specific CD4+T-Cell reactivity[J].Antimicrob Agents Chemother, 2008, 52 (1) :312-320. [10]龚非力, 梁薇, 廖纪元, 等.医学免疫学[M].北京:科学出版社, 2007:66-96. [11]王玫, 聂向民, 朱传福, 等.中国山东省威海, 莱芜地区健康人群HLA—A、B、DRB1等位基因频率多态性调查[J].微循环学杂志, 2006, 16 (4) :40-45. [12]黄爱春, 吴继周, 吴健林, 等.HLA-DRB1*14和*15等位基因与肝癌的相关性[J].临床肝胆病杂志, 2010, 26 (4) :240-242. -
本文二维码
计量
- 文章访问数: 2750
- HTML全文浏览量: 25
- PDF下载量: 674
- 被引次数: 0
下载:
